

For Health Professionals Who Care for People with Cancer

Inside This Issue:

Editor's Choice

New Programs

- **UGUAVERD** Erdafitinib for Advanced *FGFR3* Mutation-Positive Urothelial Carcinoma
- **LUAJPMB, LUAJPMB6** Adjuvant Pembrolizumab for NSCLC
- **LUNAPGPMB** Neoadjuvant-Adjuvant Pembrolizumab, Platinum and Gemcitabine for Squamous NSCLC
- **LUNAPPPMB** Neoadjuvant-Adjuvant Pembrolizumab, Pemetrexed and Platinum for Non-Squamous NSCLC
- **LYPOLARCHP** Polatuzumab Vedotin with Doxorubicin, Cyclophosphamide, Prednisone and Rituximab for Lymphoma

Program Updates

- **UGUPLVT** Lutetium (¹⁷⁷Lu) Vipivotide Tetraxetan (PLUVICTO®)

Practice Standards and Policies

Dose Banding: durvalumab, paclitaxel NAB, pembrolizumab

Drug Update

Paclitaxel NAB naming update

Education Corner

Drug Incompatibility with IV Bags/Tubing: Non-PVC/Non-DEHP

Cancer Drug Manual®

New erdafitinib, quizartinib

Revised mirvetuximab soravtansine

Oncology High-Alert Medications erdafitinib

Continuing Education

FPON: Neuroendocrine Tumours for Primary Care

Benefit Drug List

New UGUVERD, LUAJPMB, LUAJPMB6, LUNAPGPMB, LUNAPPPMB, LYPOLARCHP

Revised GIGAVCOXZ, GIGAVFFOXZ

Protocols, PPPOs and Patient Handouts

New CN UCNTTF GU UGUVERD LU LUAJPMB, LUAJPMB6, LUNAPGPMB, LUNAPPPMB LY LYPOLARCHP

Revised BR BRAJPEM, BRAJPN, BRAJPNCT, BRAJPN, BRAVABR, BRAVEVEX, BRAVPEM, BRAVPEM6, BRAVPGC, BRAVPP, BRAVPPN, BRLACPNAC, BRLACPNACG, BRLAPNAC, BRLAPNACG, BRPCTAC, BRPCWTAC CN CNAJZRT, CNBEV, CNELTZRT GI GIAVDUR4, GIAVDURPG, UGIAVPEM, UGIAVPEM6, GIAVPEMPG, GIGAVCOXP, GIGAVCOXZ, GIGAVFFOXP, GIGAVFFOXZ, GIGAVPCOXT, GIGAVPFOXT, GIPGEMABR, GITREMDUR GO GOBEP, GOCABR, GOCABRBEV, GOCXBP, GOCXBP6, UGOCXCATBP, UGOCXCATP, GOCXCPNBP, GOCXCPNP, UGOEAVDCAT, UGOEAVDPNC, UGOENDAVP, UGOENDAVP6, GOENDAVPL, GOENDAVPL6, GOEP GU GUAJPEM, GUAJPEM6, GUAVEVPEM, GUAVPEM, GUAVPEM6, GUAVPEMAX, GUAVPEMAX6, GUAVPEML, GUAVPEML6, GUBEP, GUEP, GUMCSPAPA, GUMCSPENZ, UGUNMPDAR, UGUNMPENZ, UGUPAPA, UGUPENZ HN HNAVPCPMB, HNAVPE, HNAVPPFMB, HNAVPMBF, HNAVPMBF6, HNAVPMBM, HNAVPMBM6, HNOTLEN LK LKCLLN LU LUAVATZ, LUAVATZ4, LUAVNIV, LUAVNIV4, LUAVPCIPNI, LUAVPCPMB, LUAVPGPMB, LUAVPMB, LUAVPMB6, LUAVPMBF, LUAVPMBF6, LUAVPMBM, LUAVPMBM6, LUAVPPMBM, LUAVPPMB, LULADUR, LULADUR4, LUMMIPNI, LUMMIPNI3, LUSCDURPE, LUSCPEPO, LUSCPEPORT LY LYPEM, LYPEM6, LYPOLABR SA SAAVGS SC SCCRS, SCICANS SM SMAJPEM, SMAJPEM6, SMAVPEM, SMAVPEM6, SMNAPEM TA UTAAVPEM, UTAAVPEM6

Resources and Contact Information

Editor's Choice

New Programs

BC Cancer Provincial Systemic Therapy has approved the following new treatment programs effective 01 February 2026. Full details of all treatment programs are available in the [Chemotherapy Protocols](#) section of the BC Cancer website.

Genitourinary

Erdafitinib for Advanced *FGFR3* Mutation-Positive Urothelial Carcinoma (UGUAVERD) – The BC Cancer Genitourinary Tumour Group is introducing erdafitinib for the treatment of patients with locally advanced unresectable or metastatic urothelial carcinoma (UC) harbouring susceptible *FGFR3* genetic alterations, and

Editor's Choice

with disease progression during at least one prior line of therapy. Fibroblast growth factor receptors (FGFRs) play a crucial role in UC, with alterations in the *FGFR* gene in approximately 20% of advanced or metastatic disease; erdafitinib is an oral selective pan-FGFR tyrosine kinase inhibitor. Erdafitinib commonly causes hyperphosphatemia, and all patients should be instructed to follow a low phosphate diet and considered for referral to a dietitian. Ocular toxicities are reported, and comprehensive eye examination and monitoring by ophthalmology or optometry is strongly recommended. More information on erdafitinib is available in the Cancer Drug Manual section in this issue. BC Cancer Compassionate Access Program (CAP) approval is required.

The randomized controlled phase III THOR trial involved patients with locally advanced or metastatic UC harbouring *FGFR3* alterations whose disease progressed after previous treatment with a checkpoint inhibitor.^{1,2} Compared with chemotherapy, erdafitinib was associated with benefit in objective response rate, progression-free survival (PFS) and overall survival (OS). The most common treatment-related adverse events of grade 3 or higher with erdafitinib were palmar-plantar erythrodysesthesia, stomatitis, onycholysis and hyperphosphatemia.

Lung

The BC Cancer Lung Tumour Group is implementing new adjuvant and neoadjuvant-adjuvant treatment programs using pembrolizumab in non-small cell lung cancer (NSCLC).

Adjuvant Pembrolizumab for NSCLC (LUAJPMB, LUAJPMB6) – Adjuvant pembrolizumab monotherapy is approved for patients with stage 1B to IIIA NSCLC and with PD-L1 tumour proportion score (TPS) less than 50%. Eligible patients should have undergone complete surgical resection with no clinical or radiographic evidence of disease. Pembrolizumab must be initiated within 12 weeks of completion of platinum-based chemotherapy.

The randomized, controlled phase III KEYNOTE-091 trial in patients with stage 1B to IIIA NSCLC compared adjuvant treatment with pembrolizumab to placebo for approximately one year.^{3,4} After a median follow-up of nearly 4 years, disease-free survival (DFS) was prolonged in the pembrolizumab group regardless of PD-L1 expression. The adverse event profile of pembrolizumab was considered manageable and consistent with the known side effects of immune checkpoint inhibitors.

Neoadjuvant-Adjuvant Treatment for NSCLC:

Pembrolizumab, Platinum and Gemcitabine for Squamous NSCLC	(LUNAPGPMB)
Pembrolizumab, Pemetrexed and Platinum for Non-Squamous NSCLC	(LUNAPPPMB)

Neoadjuvant-adjuvant pembrolizumab, in combination with platinum-based chemotherapy, is approved for patients with previously untreated resectable stage II to IIIB NSCLC, irrespective of PD-L1 status. Patients receive pembrolizumab and chemotherapy in the neoadjuvant phase, followed by adjuvant pembrolizumab monotherapy starting at least 4 weeks but no later than 12 weeks after surgery.

The randomized, controlled phase III KEYNOTE-671 trial was undertaken in patients with resectable stage II to IIIB NSCLC, who were eligible for surgical resection and perioperative systemic therapy.^{5,6,7} Patients were randomized to receive pembrolizumab or placebo (in combination with neoadjuvant platinum-based chemotherapy and as adjuvant monotherapy following surgery). The addition of pembrolizumab to

Editor's Choice

treatment resulted in improved event-free survival (EFS) and OS. The adverse event profile of pembrolizumab was consistent with its known safety profile.

Lymphoma

Polatuzumab Vedotin with Doxorubicin, Cyclophosphamide, Prednisone and Rituximab for Lymphoma (LYPOLARCHP) – The BC Cancer Lymphoma Tumour Group is implementing treatment with polatuzumab vedotin in combination with doxorubicin, cyclophosphamide, prednisone and rituximab (R-CHP), as the new standard of care in patients with newly diagnosed CD20-positive diffuse large B-cell lymphoma (DLBCL) classified as activated B cell-like (ABC) subtype, confirmed with gene expression profiling. This curative-intent treatment protocol is an adaptation of standard CHOP-R, with polatuzumab vedotin replacing vincristine. Due to anticipated neutropenia with polatuzumab vedotin-R-CHP, empiric filgrastim is administered with each cycle.

The randomized controlled phase III POLARIX trial investigated the use of polatuzumab vedotin in patients with previously untreated DLBCL.^{8,9} In a subgroup analysis of patients with ABC subtype, treatment with polatuzumab vedotin-R-CHP showed improvement in PFS and OS compared to CHOP-R. Less patients in the polatuzumab group required secondary therapies for persistent or relapsed disease including systemic therapy, radiation therapy, stem cell transplantation or CAR T-cell therapy. The overall toxicity profiles of the regimens were comparable, with no difference in the frequency of neuropathy; however, febrile neutropenia and infections occurred more frequently in the polatuzumab vedotin group.

References:

1. Canada's Drug Agency (CDA-AMC). Reimbursement Recommendation. Erdafitinib (Balversa®). *Canadian Journal of Health Technologies* 2025;5(1):1-25. <https://doi.org/10.51731/cjht.2025.1067>
2. Loriot Y, Matsubara N, Park SH, et al. Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma. *N Engl J Med* 2023;389(21):1961-71. <https://doi.org/10.1056/NEJMoa2308849>
3. Canada's Drug Agency (CDA-AMC). Reimbursement Recommendation. Pembrolizumab (Keytruda®). *Canadian Journal of Health Technologies* 2025;5(2):1-25. <https://doi.org/10.51731/cjht.2025.1081>
4. O'Brien M, Paz-Ares L, Marreaud S, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIa non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. *Lancet Oncol* 2022;23:1274-1286. [https://doi.org/10.1016/S1470-2045\(22\)00518-6](https://doi.org/10.1016/S1470-2045(22)00518-6)
5. Canada's Drug Agency (CDA-AMC). Reimbursement Recommendation. Pembrolizumab (Keytruda®). *Canadian Journal of Health Technologies* 2025;5(4):1-25. <https://doi.org/10.51731/cjht.2025.1116>
6. Wakelee H, Liberman M, Kato T, et al. Perioperative pembrolizumab for early-stage non-small-cell lung cancer. *N Engl J Med* 2023;389(6):491-503. <https://doi.org/10.1056/NEJMoa2302983>
7. Spicer JD, Garassino MC, Wakelee H, et al. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 2024;404(10590):1240-1252. [https://doi.org/10.1016/S0140-6736\(24\)01756-2](https://doi.org/10.1016/S0140-6736(24)01756-2)
8. Canada's Drug Agency (CDA-AMC). Reimbursement Recommendation. Polatuzumab Vedotin (Polivy®). *Canadian Journal of Health Technologies* 2025;5(7):1-29. <https://doi.org/10.51731/cjht.2025.1175>
9. Tilly H, Morschhauser F, Sehn, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. *N Engl J Med* 2022;386(4):351-363. <https://doi.org/10.1056/NEJMoa2115304>

Program Updates

Genitourinary

Lutetium ¹⁷⁷Lu Vipivotide Tetraxetan (PLUVICTO®) for Metastatic Castration-Resistant Prostate Cancer

- A new [Referral Form](#) is available for treatment with lutetium (¹⁷⁷Lu) vipivotide tetraxetan (UGUPLVT)

Practice Standards and Policies

All Systemic Therapy policies and procedures are on the BC Cancer page of [Shared Health Organizations Portal \(SHOP\)](#).

Dose Banding: Durvalumab, Paclitaxel NAB, Pembrolizumab

As part of the continued dose banding rollout at BC Cancer:

- standardized dose bands for **durvalumab**, **paclitaxel NAB** and **pembrolizumab** have been integrated into all protocols, provincial preprinted orders (PPPOs) and the Cerner system
- dose banding will continue with avelumab, enfortumab vedotin, sacituzumab govitecan, trastuzumab, trastuzumab deruxtecan and trastuzumab emtansine in March 2026
- Systemic Therapy [Procedure III-140: Management of Dose Banded Cancer Drug Treatments](#) continues to be updated to reflect the drugs approved for dose banding
- [Dose Banding Tables](#) are posted in the Cancer Drug Manual[®] Appendix

Drug Update

Paclitaxel NAB naming update

In conjunction with the paclitaxel NAB dose banding implementation, paclitaxel NAB naming is being updated with the removal of the brand name ABRAXANE[®] from all BC Cancer documents and systems including protocols, provincial preprinted orders (PPPOs) and Cerner:

- PACLitaxel NAB (ABRAXANE) is being replaced with **PACLitaxel NAB**

Education Corner

Drug Incompatibility with IV Containers & Tubing: Non-PVC and Non-DEHP Terminology

Background

Intravenous (IV) containers (including IV bags, medication ports, and administration ports) and IV tubing are made of plastic materials, most commonly polyvinyl chloride (PVC). Pharmacy and nursing staff, however, are often advised to use *non-DEHP* IV containers and tubing for the preparation and/or administration of certain injectable drugs. Because the differences between the materials used for IV containers/tubing are not commonly understood, the terminology used to identify those differences creates confusion for staff.

What plastic materials are used in IV containers and tubing?

Polyvinyl chloride (PVC) is one of the most-used plastic materials due to its durability and versatility. It is a rigid plastic that must be softened with the addition of a plasticizer. Alternative (non-PVC) types of plastic, which are naturally flexible and do not require a plasticizer, are also used.

Plastic Material	Description	Examples
PVC	Rigid, requires plasticizer to make it flexible	PVC = polyvinyl chloride
Non-PVC	Flexible, does not require plasticizer	Polyolefin Family of thermoplastics made from simple olefins (alkenes) Examples: polyethylene, polypropylene
		EVA = ethylene vinyl acetate A copolymer made from ethylene and vinyl acetate

Why PVC may be an issue for drug compatibility?

Some drug products may irreversibly adhere to (adsorption) or absorb into (absorption) PVC material, particularly if they are lipophilic (e.g., amiodarone, carmustine, thiotepa). As a result, the full dose of the drug may not be delivered to the patient. Therefore, these drug products are generally considered incompatible with PVC. To prevent adsorption/absorption to PVC material, these drug products should be prepared and administered using non-PVC containers/tubing (Appendix).

What are plasticizers and why are they used in IV containers and tubing?

A plasticizer is a substance added to some types of plastic material (such as PVC) to make that material more flexible, resilient, and easier to handle. There are dozens of plasticizers in commercial use. Diethylhexyl phthalate (DEHP) is the most-used plasticizer in PVC containers/tubing.

Plasticizer	Description	Examples
DEHP	Widely-used plasticizer	DEHP = diethylhexyl phthalate
Non-DEHP	Phthalate plasticizers	DINP = diisononyl phthalate DEHT = di-[2-ethylhexyl] phthalate
	Non-phthalate plasticizers	TOTM = trioctyl trimellitate DINCH = di-isononyl cyclohexane-1,2-dicarboxylate

Why DEHP plasticizer is an issue for drug compatibility?

Some drug products (e.g., etoposide) interact with the DEHP plasticizer that has been added to the PVC used in IV containers/tubing. This can cause DEHP to leach from the PVC material into the drug solution where it will be administered to the patient. DEHP is possibly carcinogenic (IARC Group 2B) and presumed toxic to human reproduction (EC Category 1B) based on estimated risks from lifelong continuous exposure.

For adult patients, the impact of DEHP exposure from IV administration of affected drug products is likely limited because food is considered the primary source of exposure to DEHP. Nevertheless, as a precaution, it is recommended that drugs that can leach DEHP from PVC are prepared and administered using containers/tubing made of plastic materials without added DEHP plasticizer (*non-DEHP* containers/tubing) to avoid unnecessary exposure to DEHP (Appendix).

Education Corner

PVC containers/tubing that are made with alternative plasticizers (such as TOTM) do not contain DEHP and can, therefore, be used for drug products that leach DEHP.

Why PVC and DEHP are NOT synonymous?

Non-PVC is usually non-DEHP

PVC containers and tubing usually contain DEHP as the added plasticizer. This makes them unsuitable for drugs that can leach DEHP from the PVC.

In contrast, most non-PVC materials (e.g., polyolefin, EVA) do not require added plasticizer. Therefore, non-PVC containers/tubing are usually designated as *non-DEHP*, and their packaging is often labelled as both **non-PVC** and **non-DEHP**.

Non-DEHP is NOT always non-PVC

To be considered non-PVC, containers/tubing should be made of non-PVC materials. Some are made of PVC but are still designated as *non-DEHP*, because:

- they use alternative plasticizers (e.g., TOTM), or
- they are lined with a non-PVC material (e.g., polyolefin) that prevents the drug from interacting with the PVC material

In these examples, the packaging is labelled only as **non-DEHP**.

APPENDIX: Quick Guide to Drug Incompatibility with IV Container & Tubing Materials

Drug Requirements	IV Container & Tubing Materials *				
	PVC with DEHP	Polyolefin †	EVA	PVC with alternative plasticizer ‡	PVC with polyolefin lining
Non-DEHP §	No	Yes	Yes	Yes	Yes
Non-PVC ¶	No	Yes	Yes	No	Yes
Non-DEHP, Non-PVC	No	Yes	Yes	No	Yes

* If unclear from the packaging label, confirm with IV container/tubing manufacturer that all components along the fluid path of the container/tubing are made of compatible materials, including medication and administration ports

† e.g., polyethylene, polypropylene

‡ e.g., DINP, DEHT, TOTM, DINCH

§ e.g., blinatumomab, cabazitaxel, docetaxel, etoposide, ixabepilone, mirvetuximab soravtansine, paclitaxel, temsirolimus, teniposide

¶ e.g., thiotepa

[Drug Incompatibility with IV Containers & Tubing: Non-PVC/Non-DEHP Guide](#) is available in the Chemotherapy Preparation and Stability Chart section of the Cancer Drug Manual[®].

Developed by M de Lemos, N Badry, A Dar Santos, V Kletas and R Latt (Provincial Pharmacy)

Education Corner

References:

1. Bello W, Pezzatti J, Stampfli C, et al. A critical opinion-based review of hospital pharmacy compounding with respect to the risk of leachable substances due to the off-label use of plastic primary packaging. *Ther Adv Drug Saf* 2025;16. <https://doi.org/10.1177/20420986251317424>
2. Jin SE, You S, Jeon S, et al. Evaluation of drug sorption to PVC- and non-PVC-based tubes in administration sets using a pump. *J Vis Exp* 2017;(121):55086. <https://doi.org/10.3791/55086>
3. Sahnoune M, Tokhadzé N, Devémy J, et al. Understanding and characterizing the drug sorption to PVC and PE materials. *ACS Appl Mater Interfaces* 2021;13(16):18594-18603. <https://doi.org/10.1021/acsami.1c03284>
4. Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR). Opinion on the safety of medical devices containing DEHP-plasticized PVC or other plasticizers on neonates and other groups possibly at risk (2015 update). European Commission: Luxembourg, 03 December 2015. <https://doi.org/10.2772/45179>

Cancer Drug Manual[©]

All documents are available in the [Cancer Drug Manual[©]](#) on the BC Cancer website.

New Documents

The **Erdafitinib Monograph** and **Patient Handout** have been developed with expert review provided by Dr. Krista Noonan (medical oncologist, BC Cancer Genitourinary Tumour Group) and Jelena Mucovic (tumour group pharmacist, BC Cancer Provincial Pharmacy). Erdafitinib is an orally administered kinase inhibitor that selectively targets fibroblast growth factor receptor (FGFR) 1,2,3, and 4. It is used in the treatment of bladder cancers harbouring an *FGFR3* mutation. The usual starting dose is 8 mg once daily. Dosing follows BC Cancer Protocol UGUVERD.

Highlights from these documents include:

- dose may be increased to 9 mg daily based on tolerability and serum phosphate levels
- hyperphosphatemia is common; patients are advised to avoid taking nonprescription medications and supplements which may increase phosphate levels, especially prior to the initial dose modification period
- central serous retinopathy and other ocular toxicities are reported; ophthalmologic exams are recommended prior to starting treatment and then regularly thereafter

Erdafitinib has been added to the **Auxiliary Label List** and has been evaluated for the **BC Health Authorities Provincial Hazardous Drug List**.

Note that the following drug is not a BC Cancer Benefit Drug and requires application to the BC Cancer Compassionate Access Program (CAP). The corresponding Interim Monograph and Patient Handout are made available for reference only.

The **Quizartinib Interim Monograph** and **Patient Handout** have been developed with expert review provided by Dr. David Sanford (hematologist, BC Cancer Leukemia and Bone Marrow Transplant Tumour Group) and Robert Tillmanns (tumour group pharmacist, BC Cancer Provincial Pharmacy). Quizartinib is an orally administered inhibitor of FMS-like tyrosine kinase 3 (FLT3). It is used in the treatment of acute myeloid leukemia harbouring *FLT3*-internal tandem duplication. Quizartinib is administered as part of a

Cancer Drug Manual[©]

multiphase regimen; it is combined with chemotherapy during the induction and consolidation phases, followed by quizartinib monotherapy in the maintenance phase.

Highlights from these documents include:

- QTc prolongation, torsades de pointes and cardiac arrest have been reported with quizartinib; correct preexisting electrolyte disturbances prior to treatment and monitor ECG and electrolytes
- quizartinib dose reduction may be required for drug interactions involving the CYP 3A4/5 metabolic pathway

Quizartinib has been added to the **Auxiliary Label List** and has been evaluated for the **BC Health Authorities Provincial Hazardous Drug List**.

Revised Documents

Mirvetuximab Soravtansine Interim Monograph

Common Trade Name(s): deleted identified countries because drug has been marketed in Canada and all countries use common brand name

Supply and Storage: updated manufacturer

Solution Preparation and Compatibility: updated recommended filter type

Parenteral Administration: updated recommended filter type

Oncology High-Alert Medications List

Erdafitinib has been added to the [Oncology High-Alert Medications List](#).

Continuing Education

FPON: Neuroendocrine Tumours for Primary Care

The Family Practice Oncology Network (FPON) is pleased to announce a webinar on **Neuroendocrine Tumours for Primary Care** with Dr. Joao Paulo Solar Vasconcelos. The webinar is Thursday 19 February 2026, from 0800-0900h, as part of the accredited, complimentary FPON webcasts.

By the end of the session, participants will be able to:

- Recognize signs and symptoms suggestive of neuroendocrine tumours
- Describe the diagnostic work-up
- Review management options thereof

For more information and link to registration, visit:

[UBC CPD | FPON Webinar: Neuroendocrine Tumours for Primary Care](#)

Benefit Drug List

New Programs

The following treatment programs have been added to the BC Cancer [Benefit Drug List](#) effective 01 February 2026:

Protocol Title	Protocol Code	Benefit Status
Treatment of Advanced <i>FGFR3</i> Mutation-Positive Urothelial Carcinoma using Erdafitinib	UGUAVERD	Restricted
Adjuvant Treatment of Non-Small Cell Lung Cancer using Pembrolizumab	LUAJPMB	Class I
Adjuvant Treatment of Non-Small Cell Lung Cancer using 6-Weekly Pembrolizumab	LUAJPMB6	Class I
Neoadjuvant-Adjuvant Treatment of Squamous Non-Small Cell Lung Cancer with Platinum, Gemcitabine and Pembrolizumab	LUNAPGPMB	Class I
Neoadjuvant-Adjuvant Treatment of Non-Squamous Non-Small Cell Lung Cancer with Pemetrexed, Platinum and Pembrolizumab	LUNAPPPMB	Class I
Treatment of Lymphoma with Doxorubicin, Cyclophosphamide, Prednisone, Rituximab and Polatuzumab Vedotin	LYPOLARCHP	Class I

Revised Programs

The following treatment programs have been revised on the BC Cancer [Benefit Drug List](#) effective 01 February 2026:

Protocol Title	Protocol Code	Benefit Status
Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction (GEJ) or Esophageal Adenocarcinoma using Capecitabine, Oxaliplatin and Zolbetuximab	GIGAVCOXZ	Class I
Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction (GEJ) or Esophageal Adenocarcinoma using Oxaliplatin, Fluorouracil, Leucovorin and Zolbetuximab	GIGAVFFOXZ	Class I

Highlights of New & Revised Protocols, PPPOs and Patient Handouts

BC Cancer Treatment Protocols, Provincial Preprinted Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below, with document revisions indicated in the respective columns. Protocol codes for treatment requiring BC Cancer Compassionate Access Program (CAP) approval are prefixed with the letter **U**.

NEW Protocols, PPPOs and Patient Handouts (*new documents checked*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
UCNTTF	Palliative Therapy of Glioblastoma using Tumour Treating Fields (OPTUNE GIO®)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
UGUAVERD	Treatment of Advanced <i>FGFR3</i> Mutation-Positive Urothelial Carcinoma using Erdafitinib	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
LUAJPMB	Adjuvant Treatment of Non-Small Cell Lung Cancer using Pembrolizumab	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
LUAJPMB6	Adjuvant Treatment of Non-Small Cell Lung Cancer using 6-Weekly Pembrolizumab	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
LUNAPGPMB	Neoadjuvant-Adjuvant Treatment of Squamous Non-Small Cell Lung Cancer with Platinum, Gemcitabine and Pembrolizumab	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Neoadjuvant PPPO Adjuvant PPPO	<input type="checkbox"/>
LUNAPPPMB	Neoadjuvant-Adjuvant Treatment of Non-Squamous Non-Small Cell Lung Cancer with Pemetrexed, Platinum and Pembrolizumab	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Neoadjuvant PPPO Adjuvant PPPO	<input type="checkbox"/>
LYPOLARCHP	Treatment of Lymphoma with Doxorubicin, Cyclophosphamide, Prednisone, Rituximab and Polatuzumab Vedotin	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
BR Breast				
BRAJPEM	Adjuvant Treatment of Resected Triple-Negative Breast Cancer using Pembrolizumab	<i>Dose banding added; tests clarified; contact physician updated</i>	<i>Dose banding added; treatment and tests clarified; height and BSA removed</i>	---
BRAJPN	Alternative Adjuvant Therapy for Breast Cancer using Paclitaxel NAB	<i>Dose banding added; contact physician, tests and dose modifications clarified; ABRAXANE brand name deleted</i>	<i>Dose banding added; treatment and tests clarified; ABRAXANE brand name deleted</i>	<i>ABRAXANE brand name deleted</i>

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
BRAJPNT	Alternative Neoadjuvant or Adjuvant Therapy for Breast Cancer using Paclitaxel NAB, Carboplatin and Trastuzumab	<i>Dose banding added; contact physician, units of measure and dose modifications clarified; ABRAXANE brand name deleted</i>	<i>Dose banding added; treatment and tests clarified; ABRAXANE brand name deleted</i>	<i>ABRAXANE brand name deleted</i>
BRAJPNT	Alternative Adjuvant Therapy for Breast Cancer using Paclitaxel NAB and Trastuzumab	<i>Dose banding added; tests, dose modifications, units of measure and contact physician clarified; ABRAXANE brand name deleted</i>	<i>Dose banding added; units of measure, treatment and tests clarified; ABRAXANE brand name deleted</i>	<i>ABRAXANE brand name deleted</i>
BRAVABR	Palliative Therapy for Metastatic Breast Cancer using Paclitaxel NAB	<i>Dose banding added; eligibility, exclusions, tests, dose modifications and contact physician clarified; ABRAXANE brand name deleted</i>	<i>Dose banding added; tests and treatment clarified; ABRAXANE brand name deleted</i>	---
BRAVEVEX	Therapy for Advanced Breast Cancer using Everolimus and Exemestane	<i>Reference to cycles deleted; contact physician updated; dose modifications clarified</i>	<i>Reference to cycles deleted; premedications and treatment clarified</i>	---
BRAVPEM	Treatment of Metastatic Breast Cancer using Pembrolizumab	<i>Eligibility, contact physician and treatment updated; dose banding added</i>	<i>Dose banding added; treatment and tests clarified; height and BSA removed</i>	---
BRAVPEM6	Treatment of Metastatic Breast Cancer using 6-Weekly Pembrolizumab	<i>Eligibility, contact physician and treatment updated; dose banding added</i>	<i>Dose banding added; treatment and tests clarified; height and BSA removed</i>	---
BRAVPGC	Palliative Therapy for Metastatic Breast Cancer using Pembrolizumab, Gemcitabine and Carboplatin	<i>Eligibility and treatment updated; dose banding added; ABRAXANE brand name deleted; contact physician and tests clarified</i>	<i>Dose banding added; tests clarified</i>	---
BRAVPP	Palliative Therapy for Metastatic Breast Cancer using Pembrolizumab with Paclitaxel	<i>Eligibility and treatment updated; dose banding added; contact physician, tests and units of measure clarified; ABRAXANE brand name deleted</i>	<i>Dose banding added; tests and units of measure clarified</i>	---

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
BRAVPPN	Palliative Therapy for Metastatic Breast Cancer using Pembrolizumab and Paclitaxel NAB	<i>Eligibility and treatment updated; dose banding added; contact physician, tests and dose modifications clarified; Abraxane brand name deleted</i>	<i>Dose banding added; tests clarified; ABRAXANE brand name deleted</i>	<i>ABRAXANE brand name deleted</i>
BRLACPNAC	Alternative Neoadjuvant Therapy for Triple-Negative Breast Cancer using Carboplatin and Paclitaxel NAB followed by Doxorubicin and Cyclophosphamide	<i>Dose banding added; contact physician, treatment and dose modifications clarified; ABRAXANE brand name delete</i>	<i>Dose banding added; treatment clarified; ABRAXANE brand name deleted</i>	<i>ABRAXANE brand name deleted</i>
BRLACPNACG	Alternative Neoadjuvant Therapy for Triple-Negative Breast Cancer using Dose-Dense Therapy: Carboplatin and Paclitaxel NAB followed by Doxorubicin and Cyclophosphamide	<i>Dose banding added; contact physician, units of measure and dose modifications clarified; ABRAXANE brand name deleted</i>	<i>Dose banding added; treatment clarified; ABRAXANE brand name deleted</i>	<i>ABRAXANE brand name deleted</i>
BRLAPNAC	Alternative Neoadjuvant Therapy for Locally Advanced Breast Cancer using Paclitaxel NAB followed by Doxorubicin and Cyclophosphamide	<i>Dose banding added; treatment, dose modifications and contact physician clarified; ABRAXANE brand name deleted</i>	<i>Dose banding added; treatment clarified; ABRAXANE brand name deleted</i>	<i>ABRAXANE brand name deleted</i>
BRLAPNACG	Alternative Neoadjuvant Therapy for Breast Cancer using Dose-Dense Therapy: Paclitaxel NAB followed by Doxorubicin and Cyclophosphamide	<i>Dose banding added; contact physician, treatment and dose modifications clarified; ABRAXANE brand name deleted</i>	<i>Dose banding added; treatment and return appointment orders clarified; ABRAXANE brand name deleted</i>	<i>ABRAXANE brand name deleted</i>
BRPCTAC	Neoadjuvant Therapy for Triple-Negative Breast Cancer using Pembrolizumab with Carboplatin and Weekly Paclitaxel followed by Doxorubicin and Cyclophosphamide	<i>Dose banding added; contact physician, tests, treatment and dose modifications clarified</i>	<i>Dose banding added; treatment and tests clarified</i>	---
BRPCWTAC	Neoadjuvant Therapy for Triple-Negative Breast Cancer using Pembrolizumab, Weekly Carboplatin and Weekly Paclitaxel, followed by Doxorubicin and Cyclophosphamide	<i>Dose banding added; contact physician, tests and dose modifications clarified</i>	<i>Dose banding added; treatment, tests and return appointment orders clarified</i>	---
CN Neuro-Oncology				
CNAJTZRT	Concomitant (Dual Modality) and Adjuvant Temozolomide for Newly Diagnosed Malignant Gliomas with Radiation	<i>Tests updated</i>	<i>Tests updated</i>	---
CNBEV	Palliative Therapy for Recurrent Malignant Gliomas using Bevacizumab with or without Concurrent Etoposide or Lomustine	---	---	<i>Treatment clarified</i>

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
CNELTZRT	Treatment of Elderly Newly Diagnosed Glioma Patient with Concurrent and Adjuvant Temozolomide and Radiation Therapy	<i>Tests updated</i>	<i>Tests updated</i>	---
GI Gastrointestinal				
GIAVDUR4	Treatment of Advanced Biliary Tract Cancer using Durvalumab	<i>Dose banding added; tests clarified</i>	<i>Dose banding added; height and BSA removed</i>	---
GIAVDURPG	First-Line Palliative Treatment of Advanced Biliary Tract Cancer using Durvalumab, Gemcitabine and Platinum	<i>Dose banding added; premedications, dose modifications, precautions and contact physician sections clarified</i>	<i>Dose banding added; return appointment orders clarified</i>	---
UGIAVPEM	First-Line Treatment of dMMR/MSI-H Metastatic Colorectal Cancer using Pembrolizumab	<i>Eligibility and treatment updated; dose banding added</i>	<i>Dose banding added; treatment and tests clarified; height and BSA removed</i>	---
UGIAVPEM6	First-Line Treatment of dMMR/MSI-H Metastatic Colorectal Cancer using 6-Weekly Pembrolizumab	<i>Eligibility and treatment updated; dose banding added</i>	<i>Dose banding added; treatment and tests clarified; height and BSA removed</i>	---
GIAVPEMPG	First-Line Palliative Treatment of Advanced Biliary Tract Cancer using Pembrolizumab, Gemcitabine and Platinum	<i>Eligibility, contact physician and treatment updated; dose banding added</i>	<i>Dose banding added; treatment and return appointment orders clarified</i>	---
GIGAVCOXP	First-Line Treatment of Locally Advanced or Metastatic Gastroesophageal Cancer using Oxaliplatin, Capecitabine and Pembrolizumab	<i>Eligibility, contact physician and treatment updated; dose banding added</i>	<i>Dose banding added; treatment clarified</i>	---
GIGAVCOXZ	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction (GEJ) or Esophageal Adenocarcinoma using Capecitabine, Oxaliplatin and Zolbetuximab	<i>Title and eligibility updated</i>	---	---
GIGAVFFOXP	First-Line Treatment of Locally Advanced or Metastatic Gastroesophageal Cancer using Oxaliplatin, Fluorouracil, Leucovorin and Pembrolizumab	<i>Eligibility, contact physician and treatment updated; dose banding added</i>	<i>Dose banding added; tests and treatment clarified</i>	---
GIGAVFFOXZ	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction (GEJ) or Esophageal Adenocarcinoma using Oxaliplatin, Fluorouracil, Leucovorin and Zolbetuximab	<i>Title and eligibility updated</i>	---	---
GIGAVPCOXT	Treatment of Advanced Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma using Pembrolizumab, Capecitabine, Oxaliplatin and Trastuzumab	<i>Eligibility and treatment updated; dose banding added; contact physician and tests clarified</i>	<i>Dose banding added; treatment clarified</i>	---

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
GIGAVPFFOXT	Treatment of Advanced Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma using Pembrolizumab, Oxaliplatin, Fluorouracil, Leucovorin and Trastuzumab	<i>Eligibility and treatment updated; dose banding added; contact physician, tests and units of measure clarified</i>	<i>Dose banding added; treatment and tests clarified</i>	---
GIGEMABR	First-Line Treatment of Locally Advanced and Metastatic Pancreatic Cancer with Paclitaxel NAB and Gemcitabine	<i>Dose banding added; eligibility, exclusion, dose modifications and contact physician clarified; ABRAXANE brand name deleted</i>	<i>Dose banding added; treatment clarified; ABRAXANE brand name deleted</i>	<i>ABRAXANE brand name deleted</i>
GITREMDUR	First-Line Treatment of Advanced Hepatocellular Carcinoma using Tremelimumab and Durvalumab	<i>Dose banding added; tests, contact physician clarified</i>	<i>Dose banding added; treatment clarified; tests updated, height and BSA removed</i>	---
GO Gynecologic Oncology				
GOBEP	Therapy of Ovarian Germ Cell Cancer using Bleomycin, Etoposide, and Cisplatin	<i>Filgrastim use, premedications and precautions updated; eligibility, exclusions, tests, units of measure and treatment sequence clarified</i>	<i>Premedications and return appointment orders updated; units of measure clarified</i>	---
GOCABR	Alternative Treatment of Gynecological Malignancies using Carboplatin and Paclitaxel NAB	<i>Dose banding added; dose modifications clarified; ABRAXANE brand name deleted</i>	<i>Dose banding added; treatment clarified; ABRAXANE brand name deleted</i>	<i>ABRAXANE brand name deleted</i>
GOCABRBEV	Alternative Treatment of Gynecological Malignancies using Bevacizumab, Carboplatin and Paclitaxel NAB	<i>Dose banding added; dose modifications clarified; ABRAXANE brand name deleted</i>	<i>Dose banding added; tests and treatment clarified; ABRAXANE brand name deleted</i>	<i>ABRAXANE brand name deleted</i>
GOCXBP	Maintenance Therapy of Squamous, Adenocarcinoma or Adenosquamous Cancer of the Cervix with Pembrolizumab with or without Bevacizumab	<i>Eligibility and treatment updated; dose banding and TALLman lettering added</i>	<i>Dose banding added; tests clarified; height and BSA fields deleted</i>	---
GOCXBP6	Maintenance Therapy of Squamous, Adenocarcinoma or Adenosquamous Cancer of the Cervix with 6-Weekly Pembrolizumab with or without Bevacizumab	<i>Eligibility and treatment updated; dose banding and TALLman lettering added; tests clarified</i>	<i>Dose banding added; tests clarified; height and BSA deleted</i>	---
UGOCXCATBP	Primary Treatment of Squamous, Adenocarcinoma or Adenosquamous Cancer of the Cervix with Bevacizumab, Carboplatin, Paclitaxel and Pembrolizumab	<i>Eligibility and treatment updated; dose banding and TALLman lettering added; tests and dose modifications clarified</i>	<i>Dose banding added; tests clarified</i>	---

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
UGOCXCATP	Primary Treatment of Squamous, Adenocarcinoma or Adenosquamous Cancer of the Cervix with Carboplatin, Paclitaxel and Pembrolizumab	<i>Eligibility and treatment updated; dose banding added; tests and dose modifications clarified</i>	<i>Dose banding added; tests clarified</i>	---
GOCXCPNBP	Alternative Treatment of Squamous, Adenocarcinoma or Adenosquamous Cancer of the Cervix with Bevacizumab, Carboplatin, Paclitaxel NAB and Pembrolizumab	<i>Eligibility and treatment updated; dose banding added; dose modifications clarified; ABRAXANE brand name deleted</i>	<i>Dose banding added; tests clarified; ABRAXANE brand name deleted</i>	---
GOCXCPNP	Alternative Treatment of Squamous, Adenocarcinoma or Adenosquamous Cancer of the Cervix with Carboplatin, Paclitaxel NAB and Pembrolizumab	<i>Eligibility and treatment updated; dose banding added; contact physician and dose modifications clarified; ABRAXANE brand name deleted</i>	<i>Dose banding added; tests and treatment clarified; ABRAXANE brand name deleted</i>	---
UGOEAVDCAT	Treatment of Microsatellite Instability-High or Mismatch Repair Deficient Endometrial Cancer using Dostarlimab with Carboplatin and Paclitaxel	<i>Dose modifications clarified</i>	<i>Return appointment orders clarified</i>	---
UGOEAVDPNC	Alternative Treatment of Microsatellite Instability-High or Mismatch Repair Deficient Endometrial Cancer using Dostarlimab with Paclitaxel NAB and Carboplatin	<i>Dose banding added; treatment and dose modifications clarified</i>	<i>Dose banding added; treatment and tests clarified</i>	---
UGOENDAVP	Treatment of Microsatellite Instability-High or Mismatch Repair Deficient Endometrial Cancer using Pembrolizumab	<i>Eligibility and treatment updated; dose banding added</i>	<i>Dose banding added; tests and treatment clarified; height and BSA deleted</i>	---
UGOENDAVP6	Treatment of Microsatellite Instability-High or Mismatch Repair Deficient Endometrial Cancer using 6-Weekly Pembrolizumab	<i>Eligibility and treatment updated; dose banding added</i>	<i>Dose banding added; tests and treatment clarified; height and BSA deleted</i>	---
GOENDAVPL	Treatment of Endometrial Cancer with Microsatellite Stability or Mismatch Repair Proficiency using Pembrolizumab and Lenvatinib	<i>Eligibility and treatment updated; dose banding added; tests clarified</i>	<i>Dose banding added; tests clarified; height and BSA deleted</i>	---
GOENDAVPL6	Treatment of Endometrial Cancer with Microsatellite Stability or Mismatch Repair Proficiency using 6-Weekly Pembrolizumab and Lenvatinib	<i>Eligibility and treatment updated; dose banding added; tests clarified</i>	<i>Dose banding added; tests clarified; height and BSA deleted</i>	---
GOEP	Therapy of Dysgerminomatous Ovarian Germ Cell Cancer using Cisplatin and Etoposide	<i>Filgrastim use, premedications and precautions updated; eligibility, tests, units of measure and treatment sequence clarified</i>	<i>Premedications and return appointment orders updated; units of measure clarified</i>	---

REVISED Protocols, PPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPO	Handout
GU Genitourinary				
GUAJPEM	Adjuvant Treatment of Resected Renal Cell Carcinoma using Pembrolizumab	<i>Dose banding added; tests clarified; contact physician updated</i>	<i>Dose banding added; treatment and tests clarified; height and BSA removed</i>	---
GUAJPEM6	Adjuvant Treatment of Resected Renal Cell Carcinoma using 6-Weekly Pembrolizumab	<i>Dose banding added; tests clarified; contact physician updated</i>	<i>Dose banding added; treatment and tests clarified; height and BSA removed</i>	---
GUAVEVPEM	First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma using Enfortumab Vedotin and Pembrolizumab	<i>Eligibility and treatment updated; dose banding added</i>	<i>Dose banding added; treatment and return appointment orders clarified</i>	---
GUAVPEM	Treatment of Locally Advanced or Metastatic Urothelial Carcinoma using Pembrolizumab	<i>Eligibility, contact physician and treatment updated; dose banding added; tests clarified</i>	<i>Dose banding added; treatment and tests clarified; height and BSA removed</i>	---
GUAVPEM6	Treatment of Locally Advanced or Metastatic Urothelial Carcinoma using 6-Weekly Pembrolizumab	<i>Eligibility, contact physician and treatment updated; dose banding added; tests clarified</i>	<i>Dose banding added; treatment and tests clarified; height and BSA removed</i>	---
GUAVPEMAX	Treatment of Metastatic Renal Cell Carcinoma using Pembrolizumab and Axitinib	<i>Eligibility and treatment updated; dose banding and TALLman lettering added; contact physician and tests clarified</i>	<i>Dose banding added; tests and treatment clarified; height and BSA deleted</i>	---
GUAVPEMAX6	Treatment of Metastatic Renal Cell Carcinoma using 6-Weekly Pembrolizumab and Axitinib	<i>Eligibility and treatment updated; dose banding and TALLman lettering added; contact physician and tests clarified</i>	<i>Dose banding added; tests and treatment clarified; height and BSA deleted</i>	---
GUAVPEML	Treatment of Metastatic Renal Cell Carcinoma using Pembrolizumab and Lenvatinib	<i>Eligibility and treatment updated; dose banding added; contact physician and dose modifications clarified</i>	<i>Dose banding added; tests and treatment clarified; height and BSA deleted</i>	---
GUAVPEML6	Treatment of Metastatic Renal Cell Carcinoma using 6-Weekly Pembrolizumab and Lenvatinib	<i>Eligibility and treatment updated; dose banding added; contact physician and dose modifications clarified</i>	<i>Dose banding added; tests clarified; height and BSA deleted</i>	---

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
GUBEP	Curative Therapy for Germ Cell Cancer using Bleomycin, Etoposide and Cisplatin	<i>Filgrastim use, premedications and precautions updated; units of measure and tests clarified</i>	<i>Premedications and return appointment orders updated; treatment and units of measure clarified</i>	---
GUEP	Etoposide-Cisplatin Protocol for Germ Cell Cancers	<i>Antiemetics and filgrastim use updated; eligibility, tests and treatment sequence clarified</i>	<i>Premedications and return appointment orders updated; units of measure clarified</i>	---
GUMCSPAPA	Treatment of Metastatic Castration-Sensitive Prostate Cancer using Apalutamide	<i>Reference to cycles deleted; contact physician updated</i>	<i>Reference to cycles deleted; treatment clarified</i>	---
GUMCSPENZ	Treatment for Metastatic Castration-Sensitive Prostate Cancer using Enzalutamide	<i>Reference to cycles deleted; contact physician updated</i>	<i>Reference to cycles deleted; treatment clarified</i>	---
UGUNMPDAR	Treatment of Non-Metastatic Castration-Resistant Prostate Cancer using Darolutamide	<i>Reference to cycles deleted; contact physician updated; eligibility and exclusions clarified</i>	<i>Reference to cycles deleted; treatment clarified</i>	---
UGUNMPENZ	Therapy for Non-Metastatic Castration-Resistant Prostate Cancer using Enzalutamide	<i>Reference to cycles deleted; contact physician updated; eligibility and exclusions clarified</i>	<i>Reference to cycles deleted; treatment clarified</i>	---
UGUPAPA	Treatment of Non-Metastatic Castration-Resistant Prostate Cancer using Apalutamide	<i>Reference to cycles deleted; contact physician updated; eligibility and exclusions clarified</i>	<i>Reference to cycles deleted; treatment clarified</i>	---
UGUPENZ	Palliative Therapy for Metastatic Castration-Resistant Prostate Cancer using Enzalutamide	<i>Reference to cycles deleted; contact physician updated</i>	<i>Reference to cycles deleted; treatment clarified</i>	---
HN Head and Neck				
HNAVPCMB	First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck with Paclitaxel, Carboplatin and Pembrolizumab	<i>Dose banding added; contact physician, tests, precautions and dose modifications clarified</i>	<i>Dose banding added; treatment and tests clarified</i>	---
HNAVPE	Treatment of Recurrent and Metastatic Squamous Cell Cancer with Platinum and Etoposide	---	<i>Treatment and tests clarified</i>	---

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
HNAVPFPMB	First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck using Platinum, Fluorouracil and Pembrolizumab	<i>Dose banding added; contact physician, treatment, units of measure and dose modifications clarified</i>	<i>Dose banding added; treatment, tests and units of measure clarified</i>	---
HNAVPMBF	First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck with Pembrolizumab	<i>Eligibility, contact physician and treatment updated; dose banding added; tests clarified</i>	<i>Dose banding added; treatment and tests clarified; height and BSA removed</i>	---
HNAVPMBF6	First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck using 6-Weekly Pembrolizumab	<i>Eligibility, contact physician and treatment updated; dose banding added; tests clarified</i>	<i>Dose banding added; treatment and tests clarified; height and BSA removed</i>	---
HNAVPMBM	Maintenance Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck with Pembrolizumab	<i>Eligibility, contact physician and treatment updated; dose banding added; tests clarified</i>	<i>Dose banding added; treatment and tests clarified; height and BSA removed</i>	---
HNAVPMBM6	Maintenance Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck using 6-Weekly Pembrolizumab	<i>Eligibility, contact physician and treatment updated; dose banding added; tests clarified</i>	<i>Dose banding added; treatment and tests clarified; height and BSA removed</i>	---
HNOTLEN	Therapy for Locally Recurrent or Metastatic, RAI-Refractory Differentiated Thyroid Cancer using Lenvatinib	<i>Reference to cycles deleted; contact physician updated</i>	<i>Reference to cycles, height and BSA deleted; tests clarified</i>	---
LK Leukemia				
LKCMLN	Treatment of Chronic Myeloid Leukemia using Nilotinib	<i>Dose modifications clarified</i>	---	---
LU Lung				
LUAVATZ	Treatment of Advanced Non-Small Cell Lung Cancer using Atezolizumab	<i>Exclusions, tests and contact physician updated</i>	---	---
LUAVATZ4	Treatment of Advanced Non-Small Cell Lung Cancer using 4-Weekly Atezolizumab	<i>Exclusions, tests and contact physician updated</i>	---	---
LUAVNIV	Treatment of Advanced Non-Small Cell Lung Cancer using Nivolumab	<i>Exclusions, tests and contact physician updated</i>	---	---
LUAVNIV4	Treatment of Advanced Non-Small Cell Lung Cancer using 4-Weekly Nivolumab	<i>Exclusions, tests and contact physician updated</i>	---	---

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
LUAVPCIPNI	First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer with Paclitaxel, Carboplatin, Ipilimumab and Nivolumab	<i>Exclusions, tests and contact physician updated</i>	---	---
LUAVPCPMB	First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer with Paclitaxel, Carboplatin and Pembrolizumab	<i>Eligibility updated; dose banding added; tests, dose modifications and contact physician clarified</i>	<i>Dose banding added; tests clarified</i>	---
LUAVPGPMB	First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer with Platinum, Gemcitabine and Pembrolizumab	<i>Eligibility updated; dose banding added; tests, contact physician and units of measure clarified</i>	<i>Dose banding added; tests and units of measure clarified</i>	---
LUAVPMB	Treatment of Advanced Non-Small Cell Lung Cancer using Pembrolizumab	<i>Eligibility, contact physician and treatment updated; dose banding added</i>	<i>Dose banding added; treatment and tests clarified; height and BSA removed</i>	---
LUAVPMB6	Treatment of Advanced Non-Small Cell Lung Cancer using 6-Weekly Pembrolizumab	<i>Eligibility, contact physician and treatment updated; dose banding added</i>	<i>Dose banding added; treatment and tests clarified; height and BSA removed</i>	---
LUAVPMBF	First-Line Treatment of Advanced Non-Small Cell Lung Cancer using Pembrolizumab	<i>Eligibility, contact physician and treatment updated; dose banding added</i>	<i>Dose banding added; treatment and tests clarified; height and BSA removed</i>	---
LUAVPMBF6	First-Line Treatment of Advanced Non-Small Cell Lung Cancer using 6-Weekly Pembrolizumab	<i>Eligibility, contact physician and treatment updated; dose banding added</i>	<i>Dose banding added; treatment and tests clarified; height and BSA removed</i>	---
LUAVPMBM	Maintenance Therapy of Advanced Non-Small Cell Lung Cancer with Pembrolizumab	<i>Eligibility, contact physician and treatment updated; dose banding added</i>	<i>Dose banding added; treatment and tests clarified; height and BSA removed</i>	---
LUAVPMBM6	Maintenance Therapy of Advanced Non-Small Cell Lung Cancer with 6-Weekly Pembrolizumab	<i>Eligibility, contact physician and treatment updated; dose banding added</i>	<i>Dose banding added; treatment and tests clarified; height and BSA removed</i>	---
LUAVPPMBM	Maintenance Therapy of Advanced Non-Squamous Non-Small Cell Lung Cancer with Pemetrexed and Pembrolizumab	<i>Eligibility, contact physician and treatment updated; dose banding added; cautions and dose modifications clarified</i>	<i>Dose banding added; tests and treatment clarified</i>	---

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
LUAVPPMB	First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer with Platinum, Pemetrexed and Pembrolizumab	<i>Eligibility and contact physician updated; dose banding and added; eligibility, tests and units of measure clarified</i>	<i>Dose banding added; tests and units of measure clarified</i>	---
LULADUR	Treatment of Locally Advanced Non-Small Cell Lung Cancer using Durvalumab	<i>Dose banding added; tests clarified; contact physician updated</i>	<i>Dose banding added; tests clarified; height and BSA removed</i>	---
LULADUR4	Treatment of Locally Advanced Non-Small Cell Lung Cancer using 4-Weekly Durvalumab	<i>Dose banding added; tests clarified; contact physician updated</i>	<i>Dose banding added; tests clarified; height and BSA removed</i>	---
LUMMIPNI	Treatment of Malignant Mesothelioma using Ipilimumab and Nivolumab	<i>Contact physician and tests updated</i>	---	---
LUMMIPNI3	Treatment of Malignant Mesothelioma using Ipilimumab and 3-Weekly Nivolumab	<i>Contact physician and tests updated</i>	---	---
LUSCDURPE	Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with Durvalumab, Platinum and Etoposide	<i>Dose banding added; tests, units of measure and contact physician clarified</i>	<i>Dose banding added; tests and units of measure clarified</i>	---
LUSCPEPO	Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with Platinum and Oral Etoposide	---	<i>Tests and treatment clarified</i>	---
LUSCPEPORT	Treatment of Limited Stage Small Cell Lung Cancer using Platinum and Oral Etoposide with Radiation Therapy	---	<i>Tests and treatment clarified</i>	---
LY Lymphoma				
LYPEM	Treatment of Relapsed or Refractory Hodgkin Lymphoma using Pembrolizumab	<i>Eligibility, contact physician and treatment updated; dose banding added; tests clarified; contact pharmacist removed</i>	<i>Dose banding added; treatment and tests clarified; height and BSA removed</i>	---
LYPEM6	Treatment of Relapsed or Refractory Hodgkin Lymphoma using 6-Weekly Pembrolizumab	<i>Eligibility, contact physician and treatment updated; dose banding added; tests clarified</i>	<i>Dose banding added; treatment and tests clarified; height and BSA removed</i>	---
LYPOLABR	Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Not-Eligible-for Transplant using Polatuzumab Vedotin, Bendamustine and Rituximab	<i>Eligibility and contact physician updated</i>	---	---

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
SA Sarcoma				
SAAVGS	Second-Line Treatment of Advanced c-kit Positive Gastrointestinal Stromal Cell Tumours (GIST) after Imatinib using Sunitinib	<i>Tests updated; eligibility, exclusions, treatment and precautions clarified; TALLman lettering added</i>	<i>Tests updated; treatment clarified</i>	<i>Side effects and instructions updated</i>
SC Supportive Care				
SCCRS	Cytokine Release Syndrome Management	---	CRS and ICANS Patient Handout and Bispecific Antibody Patient Letter	<i>Contact information updated</i>
SCICANS	Immune Effector Cell-Associated Neurotoxicity Syndrome Management	---		
SM Skin and Melanoma				
SMAJPEM	Adjuvant Treatment of Resected Melanoma using Pembrolizumab	<i>Dose banding added; tests clarified; contact physician updated</i>	<i>Dose banding added; treatment and tests clarified; height and BSA removed</i>	---
SMAJPEM6	Adjuvant Treatment of Resected Melanoma using 6-Weekly Pembrolizumab	<i>Dose banding added; tests clarified; contact physician updated</i>	<i>Dose banding added; treatment and tests clarified; height and BSA removed</i>	---
SMAVPEM	Treatment of Unresectable or Metastatic Melanoma using Pembrolizumab	<i>Eligibility, contact physician and treatment updated; dose banding added; tests clarified</i>	<i>Dose banding added, treatment and tests clarified, height and BSA removed</i>	---
SMAVPEM6	Treatment of Unresectable or Metastatic Melanoma using 6-Weekly Pembrolizumab	<i>Eligibility, contact physician and treatment updated; dose banding added; tests clarified</i>	<i>Dose banding added; treatment and tests clarified</i>	---
SMNAPEM	Neoadjuvant-Adjuvant Treatment of Stage IIIB to IV Melanoma using Pembrolizumab	<i>Dose banding added</i>	<i>Dose banding added; treatment and tests clarified; height and BSA removed</i>	---
TA Tumour Agnostic				
UTAAVPEM	Treatment of dMMR/MSI-H Solid Tumours using Pembrolizumab	<i>Eligibility and treatment updated; dose banding added</i>	<i>Dose banding added; treatment and tests clarified; height and BSA removed</i>	---
UTAAVPEM6	Treatment of dMMR/MSI-H Solid Tumours using 6-Weekly Pembrolizumab	<i>Eligibility and treatment updated; dose banding added</i>	<i>Dose banding added; treatment and tests clarified; height and BSA removed</i>	---

Resources and Contact Information

Resource	Phone	Email / Toll Free / Fax
Systemic Therapy Update: www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update		
Systemic Therapy Update Editor	604-877-6000 x 672649	bulletin@bccancer.bc.ca
Oncology Drug Information	604-877-6275	druginfo@bccancer.bc.ca
Cancer Drug Manual Editor	250-519-5500 x 693742	nbadry@bccancer.bc.ca
Pharmacy Oncology Certification	250-712-3900 x 686820	rxchemocert@bccancer.bc.ca
CAP – Compassionate Access Program	604-877-6277	cap_bcca@bccancer.bc.ca fax 604-708-2026
OSCAR – Online System for Cancer Drugs Adjudication and Reimbursement	888-355-0355	oscar@bccancer.bc.ca fax 604-708-2051
Library/Cancer Information	604-675-8003	toll free 888-675-8001 x 8003 requests@bccancer.bc.ca
Library Document Delivery	604-675-8002	requests@bccancer.bc.ca
Pharmacy Professional Practice	604-877-6000 x 672247	mclin@bccancer.bc.ca
Professional Practice, Nursing	604-877-6000 x 672623	BCCancerPPNAdmin@phsa.ca
Provincial Systemic Therapy Network	604-877-6000 x 672247	ProvincialSystemicOffice@bccancer.bc.ca
BC Cancer – Abbotsford	604-851-4710	toll free 877-547-3777
BC Cancer – Kelowna	250-712-3900	toll free 888-563-7773
BC Cancer – Prince George	250-645-7300	toll free 855-775-7300
BC Cancer – Surrey	604-930-2098	toll free 800-523-2885
BC Cancer – Vancouver	604-877-6000	toll free 800-663-3333
BC Cancer – Victoria	250-519-5500	toll free 800-670-3322
Community Oncology Network (CON) sites: To update your contact information, please contact: bulletin@bccancer.bc.ca		

Editorial Review Board

Anne Dar Santos, BScPharm, PharmD (Editor)
 Jelena Mucovic, BScPharm (Assistant Editor)
 Mário de Lemos, PharmD, MSc(Oncol)
 Jeevan Dosanjh, RN, BScN, MN

Alina Gerrie, MD, MPH, FRCPC
 Alison Pow, BScPharm
 Yuna Jang, RN